Parkinson Disease Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Parkinson Disease remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 2,435 matched trial records and 809 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07702266 | Intervention not normalized | Not Applicable; Not yet recruiting | Centre Hospitalier Universitaire de Clermont Ferrand | France | Presence of primary parkinsonian pain according to the 3PDQ questionnaire (at day 0); Probable REM sleep behavior disorder (RBD), as identified using the RBD-1Q (REM Sleep Behavior Disorder Single-Question Screen). (at day 0) | 2027-09-30 |
| NCT07701785 | Intervention not normalized | Not Applicable; Recruiting | The Medical University of South Carolina | United States | Serious Adverse Events (Week 4, 5 minutes before and 5 minutes after stimulation sessions on Days 1-3); Feasibility of the study protocol (Week 0 through completion of study (8 weeks)) | 2028-02-01 |
| NCT07702929 | Intervention not normalized | Not Applicable; Not yet recruiting | Isfahan University of Medical Sciences | Geography not listed | Montreal Cognitive Assessment (- The day before the intervention - The day after the intervention - One month…); Cambridge Neuropsychological Test Automated Battery - Reaction Time (- The day before the intervention - The day after the intervention - One month…) | 2027-07-23 |
| NCT07703137 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Oklahoma | United States | Change in task-evoked neurovascular coupling response measured by functional near-infrared spectroscopy (Baseline to 12 weeks) | 2027-06-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (Phase 2): the indexed record reports Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.(Mean) = 68.9 % of baseline fall rate (Standard Deviation, 90.22); Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.(Mean): Median ratio = 0.973(95% CI, 0.706 - 1.274), P-Value = 0.5753; Relative Fall Rate treatment/placebo = 0.854(95% CI, 0.530 - 1.376), P-Value = 0.5156; Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.(Mean): Median ratio = 0.973(95% CI, 0.706 - 1.274), P-Value = 0.5753; Relative Fall Rate treatment/placebo = 0.854(95% CI, 0.530 - 1.376), P-Value = 0.5156.
- A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (Phase 2): the indexed record reports AE = 65 events; -; AE = 57 events.
- A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease (Phase 2): the indexed record reports Infusion 2 (Visit 3 - Week 4)(Mean) = -2.22 Score on a scale (132 points total) (Standard Deviation, 8.29); -; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including The selected trials include interventions that are not yet normalized to an asset record. Company & Deal Intelligence records identify sponsor context for Centre Hospitalier Universitaire de Clermont Ferrand, The Medical University of South Carolina, Isfahan University of Medical Sciences, University of Oklahoma. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Parkinson Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
